CARDIOL THERAPEUTICS
Commented by Armin Schulz on January 30th, 2024 | 06:30 CET
BioNTech, Cardiol Therapeutics, Evotec - Biotech upswing post-Corona
After the hype caused by the Corona vaccines, many biotech companies experienced a lull. However, there are now increasing signs of a revival, and with good reason. After a period of stagnation caused by market saturation and investor reluctance, fresh scientific breakthroughs and innovative therapeutic approaches are attracting investors and driving the sector to new heights. German biotech companies have managed to raise more funds than in the previous year despite the challenging conditions in the financial markets. Today, we look at three interesting companies and highlight their opportunities for this year.
Read
Commented by Fabian Lorenz on January 26th, 2024 | 07:00 CET
Drumbeats and Buy recommendations: Siemens Energy, SAP, Cardiol Therapeutics
Analysts at First Berlin see over 200% upside potential for the Cardiol Therapeutics share. The biotech pearl is solidly financed to implement its development pipeline. Positive Phase II data and FDA approval for a Phase III trial are expected in the second quarter of 2024, which should drive the share price. Yesterday's top performers included the shares of Siemens Energy and SAP. At Siemens Energy, the situation at subsidiary Gamesa does not appear to be as catastrophic as feared. SAP is fully committed to the Cloud and AI. Shareholders do not seem bothered by the additional costs for the transformation in 2024; instead, they are celebrating future growth opportunities.
Read
Commented by André Will-Laudien on January 2nd, 2024 | 07:10 CET
Returns beckon here: The Biotech favorites for 2024! BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys in focus
The past year was a disaster for investors in the Biotech sector - no golden check as often seen before. Despite all the gloom, the key indicator, the Nasdaq Biotechnology Index (NBI), has managed an annual gain of around 7% since the end of October, thanks to a fabulous 15% upswing. The index was temporarily down 12%. High capital costs made it difficult for research-based companies to refinance, and it is only now, with falling inflation rates, that interest rate hopes are reviving. The 10-year yield in the US fell by more than 100 basis points from 4.98% to 3.84% in a short space of time. Now, the industry senses a positive outlook again. At the end of the year, the positive environment helped some Biotech stocks shake off the negative trend and initiate a turnaround. Which stocks should we focus on?
Read
Commented by Stefan Feulner on December 28th, 2023 | 07:05 CET
Liquidia, Cardiol Therapeutics, Bristol-Myers Squibb, Pfizer - Analysts comment on their favorites
The NASDAQ Biotechnology Index has been in the green since the beginning of the year with a mini gain of 1%, but the rebound since the lows at the end of October gives hope for a much more positive stock market year 2024 for the capital-intensive sector. In addition to the multiple interest rate hikes by the central banks, the biotech sector has been weighed down, in particular, by slower progress in research and development. With the expected start of a cycle of interest rate cuts, financing and capital costs are falling, which could lead to rising prices.
Read
Commented by Fabian Lorenz on December 13th, 2023 | 07:30 CET
Several 100% upside potential? BioNTech, Bayer, Cardiol Therapeutics and Evotec in analyst check
We take a look at analysts' opinions on biotech and pharmaceutical stocks. Jefferies recently renewed its "Buy" recommendation for Evotec with a target price of EUR 34. The latest partnerships confirm that the Company's unique business model is working. The situation at Bayer is quite different. While the CEO is announcing radical changes, analysts are slashing their price targets, in some cases significantly. In contrast, analysts believe that Cardiol Therapeutics could achieve several 100% gains. The cash register is full to bursting, and an exciting news flow can be expected in 2024. At BioNTech, only the cash position is currently convincing. However, this is not enough for a buy recommendation.
Read
Commented by Armin Schulz on November 29th, 2023 | 06:30 CET
MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?
2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.
Read
Commented by Stefan Feulner on November 22nd, 2023 | 07:00 CET
Bayer, Cardiol Therapeutics, K+S AG - Clear opportunities after bottoming out
Shareholders of the chemical and pharmaceutical company Bayer suffered a black Monday following the discontinuation of a Phase III trial. As a result, Bayer shares fell to their lowest level since 2009. In contrast, there is optimism among other companies for a strong rebound. The biotech sector, in particular, seems to have bottomed out. There is a long-term opportunity for outperformance here, especially with second-tier companies.
Read
Commented by André Will-Laudien on November 7th, 2023 | 07:00 CET
Caution: New Corona wave ahead? BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys on the performance test bench
Smouldering lawsuits from vaccinated patients experiencing severe side effects have caused investors to doubt BioNTech and Pfizer in recent months. Will the plaintiffs be successful in court? This is rather unlikely, as the vaccine manufacturers can always invoke the time component in the fight against the pandemic. After all, what the WHO and all governments wanted was delivered: A quick solution! Moreover, these vaccines were finally approved by well-known health institutes. The biotech investment segment will become exciting again as winter approaches. The infection figures with the new coronavirus variants are rising noticeably again, and around 15% of the population wishes to get vaccinated. Where are the opportunities for investors?
Read
Commented by Fabian Lorenz on November 1st, 2023 | 06:10 CET
More than 300% share price opportunity: BioNTech, Morphosys and Cardiol Therapeutics
Study results, along with acquisitions by Big Pharma, are the drivers of biotech company share prices. However, in the current challenging stock market environment, even positive data can be overlooked. But this opens up opportunities for investors with a little more staying power. Sooner or later, the information is recognized, and stock prices rise, or a pharmaceutical giant makes a move. At BioNTech, for example, the price reaction to the long-awaited news from the cancer pipeline has failed to materialize. Analysts are also cautious. Cardiol Therapeutics is a different story. The Canadians have taken on the fight against heart disease and are making significant progress in their research. The share had more than doubled to EUR 1.08 by the summer. Several analysts see the current setback as a buying opportunity. Experts are also giving the thumbs up to German biotech pioneer Morphosys.
Read
Commented by Stefan Feulner on October 25th, 2023 | 07:20 CEST
BioNTech, Cardiol Therapeutics, Paion - Rising Attractiveness and Lots of Movement
The current geopolitical uncertainties with escalating conflicts in Ukraine and Israel, as well as fears of recession with continued high inflation, have also impacted the capital-intensive biotech sector. In the past week, the Nasdaq Biotech Index fell to its lowest level of the year. Since the beginning of the year, the loss amounts to almost 12%. This level should offer excellent entry opportunities for long-term investors, as many biotech companies are currently very well-positioned and attractively valued.
Read